Use of Dexmedetomidine to Improve Pain Control and Recovery After Laparocopic-Assisted Bowel Surgery in Adults

Postoperative pain control and recovery following bowel surgery remain significant clinical challenges. Although laparoscopic-assisted techniques have reduced surgical trauma compared with open procedures, many patients still experience substantial postoperative pain, delayed return of bowel function, opioid-related adverse effects, and prolonged hospitalization. These factors negatively affect patient-centered recovery outcomes and increase healthcare utilization.

Opioids remain a central component of postoperative analgesia after bowel surgery. However, opioid-based pain management is associated with well-recognized adverse effects, including nausea, vomiting, ileus, sedation, pruritus, respiratory depression, and the risk of persistent opioid use. In patients undergoing bowel surgery, these adverse effects are particularly problematic because impaired gastrointestinal motility can delay recovery and discharge. While multimodal analgesia strategies aim to reduce opioid exposure, commonly used alternatives such as nonsteroidal anti-inflammatory drugs (NSAIDs) are often contraindicated in this population, and regional anesthesia techniques (e.g., epidural analgesia or transversus abdominis plane blocks) are technically demanding, resource intensive, and not routinely used for laparoscopic-assisted procedures.

Dexmedetomidine is a selective α2-adrenergic receptor agonist with analgesic, sedative, and sympatholytic properties. Its mechanism of action includes modulation of nociceptive signaling in the spinal cord and central nervous system, reduction of sympathetic outflow, and attenuation of stress responses without clinically significant respiratory depression. Intraoperative dexmedetomidine has been shown to reduce postoperative pain scores, decrease opioid requirements, improve hemodynamic stability, and reduce postoperative nausea and vomiting in a variety of surgical populations, including abdominal surgery. Meta-analyses have also demonstrated improved recovery of bowel function associated with intraoperative dexmedetomidine use.

Despite these findings, existing studies have largely focused on intraoperative administration, and there is limited evidence regarding the potential benefits of continued dexmedetomidine infusion in the postoperative period, particularly in patients undergoing bowel surgery. This represents an important knowledge gap, as the immediate postoperative phase is when opioid exposure is highest and recovery trajectories are established. Dexmedetomidine's opioid-sparing effects, favorable sedation profile, and potential to facilitate gastrointestinal recovery suggest it may be well suited for postoperative use in this population.

The PODEX study was designed to evaluate whether a continued postoperative dexmedetomidine infusion improves recovery outcomes following laparoscopic-assisted bowel surgery. The study is a single-center, randomized, double-blind, placebo-controlled clinical trial conducted at Mount Sinai Hospital. Participants are adults undergoing elective or semi-elective laparoscopic-assisted bowel surgery who receive standardized perioperative care. All participants receive dexmedetomidine intraoperatively as part of routine anesthetic management, ensuring that the study specifically evaluates the incremental benefit of postoperative continuation of dexmedetomidine rather than its initiation during surgery.

Following surgery, participants are randomized to receive either dexmedetomidine or a matched placebo administered as a continuous intravenous infusion for up to 48 hours using a continuous ambulatory delivery device. The selected infusion rate reflects prior evidence demonstrating efficacy for analgesia and gastrointestinal recovery while minimizing risks of hypotension, bradycardia, and excessive sedation, making it appropriate for use on a surgical ward rather than an intensive care setting.

The study emphasizes patient-centered recovery using validated instruments rather than relying solely on traditional clinical endpoints. Recovery is assessed using the Quality of Recovery-15 (QoR-15) questionnaire, a multidimensional, patient-reported outcome measure that captures physical comfort, pain, emotional well-being, psychological support, and functional independence. Additional assessments evaluate pain intensity, opioid consumption, gastrointestinal recovery, length of hospital stay, and postoperative complications. Together, these measures provide a comprehensive evaluation of both subjective and objective recovery following surgery.

Dexmedetomidine is associated with known, dose-dependent cardiovascular effects, including bradycardia and hypotension, and as such, safety monitoring is an integral component of the study design. Participants are monitored for hemodynamic events, sedation, and other adverse events throughout the infusion period and follow-up. A structured monitoring protocol and predefined criteria for intervention or discontinuation are used to mitigate risk and ensure participant safety.

The statistical approach follows an intention-to-treat framework. The study is powered to detect a clinically meaningful difference in quality of recovery based on established thresholds for the QoR-15 instrument. Secondary analyses explore differences in opioid exposure, pain trajectories, gastrointestinal recovery, and hospital length of stay, providing insight into potential mechanisms underlying any observed improvement in recovery.

By focusing on postoperative continuation of dexmedetomidine in a well-defined surgical population, this study aims to generate high-quality evidence addressing an unmet need in perioperative care. If effective, postoperative dexmedetomidine infusion could represent a scalable, low-cost strategy to enhance recovery, reduce opioid-related morbidity, and improve patient experience after bowel surgery. The findings may inform future perioperative analgesia protocols and contribute to the development of evidence-based guidelines for postoperative pain management in abdominal surgery.

Inclusion criteria

• Adults aged 18-70 years.
• Undergoing elective or semi-elective laparoscopic-assisted bowel surgery (e.g., bowel resection, colectomy, ileostomy reversal).
• ASA physical status I-III.

Exclusion criteria

• Known allergy or hypersensitivity to dexmedetomidine.
• Cardiac impairment defined as:

• Moderate or severe systolic dysfunction
• Moderate or severe valvulopathy (as per American Society of Echocardiography criteria)
• Significant bradycardia (baseline heart rate < 60) or
• Heart block without a pacemaker.
• Active infection or sepsis at the time of surgery.
• Use of medications with significant interactions with dexmedetomidine (e.g., MAO inhibitors).
• Pregnant or breastfeeding individuals.
• Current opioid use (> 30 mg daily oral morphine equivalent) or history of opioid use disorder.
• Current clonidine use.
• Patients undergoing thoracic epidurals.
• Patients with liver impairment with a Child-Pugh class of B (moderate) or C (severe).